Your session is about to expire
What is Arcapta Neohaler
IndacaterolThe Generic name of this drug
Treatment SummaryIndacaterol is a medication prescribed to treat asthma and chronic obstructive pulmonary disease. It was developed by Novartis and approved by the European Medicines Agency in 2009 and the FDA in 2011. It is sold under the brand names Onbrez in Europe and Arcapta Neohaler in the US. Indacaterol is a chiral molecule, but only the pure R-enantiomer is available for use.
Arcapta Neohaleris the brand name
Arcapta Neohaler Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Arcapta Neohaler
Indacaterol
2011
4
Approved as Treatment by the FDA
Indacaterol, also called Arcapta Neohaler, is approved by the FDA for 1 uses like Chronic Obstructive Pulmonary Disease .Chronic Obstructive Pulmonary Disease
Helps manage Chronic Obstructive Pulmonary Disease (COPD)
Effectiveness
How Arcapta Neohaler Affects PatientsIndacaterol is a type of drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, which means it helps open up airways in the lungs. It is taken once a day and works for about 24 hours. Coughing is the most common side effect of this drug. Compared to other similar drugs, it has 35% more effect. When people take the drug, the cough usually starts within 15 seconds, lasts around 6 seconds, and does not cause breathing problems. Other than coughing, the safety profile of indacaterol is similar to other bronchodil
How Arcapta Neohaler works in the bodyIndacaterol helps relax the muscles in your airways, allowing them to widen and make it easier to breathe. It works by targeting adrenergic beta-2 receptors, which help the body produce a chemical called cyclic AMP. This chemical helps the airways relax, allowing more air to pass through. Indacaterol is a long-acting drug and takes effect quickly within five minutes. It is more powerful than other drugs in its class and has a high selectivity for beta-2 receptors, meaning it specifically targets these receptors without affecting other types of receptors.
When to interrupt dosage
The suggested measure of Arcapta Neohaler is contingent upon the diagnosed condition, such as Chronic Obstructive Pulmonary Disease (COPD), Maintenance and symptoms inadequately controlled with inhaled corticosteroids. The dosage fluctuates, based on the technique of delivery featured in the table beneath.Condition
Dosage
Administration
Asthma
0.075 mg, , 0.11 mg, 0.3 mg, 0.15 mg, 0.0275 mg, 0.085 mg, 0.125 mg, 0.114 mg
, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Oral; Respiratory (inhalation), Capsule - Oral; Respiratory (inhalation)
Maintenances
0.075 mg, , 0.11 mg, 0.3 mg, 0.15 mg, 0.0275 mg, 0.085 mg, 0.125 mg, 0.114 mg
, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Oral; Respiratory (inhalation), Capsule - Oral; Respiratory (inhalation)
Chronic Obstructive Pulmonary Disease
0.075 mg, , 0.11 mg, 0.3 mg, 0.15 mg, 0.0275 mg, 0.085 mg, 0.125 mg, 0.114 mg
, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Oral; Respiratory (inhalation), Capsule - Oral; Respiratory (inhalation)
Asthma
0.075 mg, , 0.11 mg, 0.3 mg, 0.15 mg, 0.0275 mg, 0.085 mg, 0.125 mg, 0.114 mg
, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Oral; Respiratory (inhalation), Capsule - Oral; Respiratory (inhalation)
Warnings
There are 20 known major drug interactions with Arcapta Neohaler.Common Arcapta Neohaler Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mobocertinib.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ziprasidone.
2,5-Dimethoxy-4-ethylthioamphetamine
Minor
The risk or severity of hypertension can be increased when Indacaterol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
5-methoxy-N,N-dimethyltryptamine
Minor
The risk or severity of hypertension can be increased when Indacaterol is combined with 5-methoxy-N,N-dimethyltryptamine.
Arcapta Neohaler Toxicity & Overdose RiskTaking too much indacaterol can cause overstimulation of the body, resulting in chest pain, high or low blood pressure, rapid heartbeat, anxiety, headache, trembling, dry mouth, palpitations, muscle cramps, nausea, dizziness, tiredness, weakness, low potassium levels, high blood sugar, and difficulty sleeping. In extreme cases, it can even lead to cardiac arrest or death.
Arcapta Neohaler Novel Uses: Which Conditions Have a Clinical Trial Featuring Arcapta Neohaler?
243 active trials are currently being conducted to assess the potential of Arcapta Neohaler in providing relief from Asthma symptoms inadequately controlled with inhaled corticosteroids and Chronic Obstructive Pulmonary Disease (COPD).Condition
Clinical Trials
Trial Phases
Maintenances
0 Actively Recruiting
Asthma
103 Actively Recruiting
Phase 4, Not Applicable, Early Phase 1, Phase 2, Phase 3, Phase 1
Chronic Obstructive Pulmonary Disease
90 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4
Asthma
0 Actively Recruiting
Arcapta Neohaler Reviews: What are patients saying about Arcapta Neohaler?
2.3Patient Review
10/2/2012 I tried this medication at the recommendation of my pulmonologist, but it made my breathing worse after just a couple weeks. I'm glad to be back on Advair.
Patient Q&A Section about arcapta neohaler
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the generic name of Arcapta Neohaler?
"Indacaterol is used to treat trouble breathing and wheezing due to a certain ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and/or emphysema). If your breathing problems are not controlled with other medication (such as a quick-relief inhaler), indacaterol may help."
Answered by AI
When was Arcapta Neohaler discontinued?
"The three drugs, Arcapta Neohaler, Utibron Neohaler and Seebri Neohaler, which were licensed by Sunovion from Novartis in December 2016, will no longer be available in the United States from April 1, 2020."
Answered by AI
Is it appropriate to use Arcapta Neohaler as a rescue bronchodilator?
"doctor
Detail
Arcapta Neohaler should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. This medication is not meant to be used for immediate relief."
Answered by AI
Why Arcapta Neohaler is discontinued?
"Arcapta Neohaler (indacaterol) was discontinued by the manufacturer (Sunovion) due to a business decision, rather than any safety concerns."
Answered by AI